Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
15 hedge funds and large institutions have $21M invested in Anebulo Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
19% more capital invested
Capital invested by funds: $17.6M → $21M (+$3.35M)
7% more funds holding
Funds holding: 14 → 15 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 28.4% → 28.18% (-0.22%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$65K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$58.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$371 |
| 5 |
JP Morgan Chase
New York
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$36.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.2K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.94K |
| 4 |
LA
LVW Advisors
Pittsford,
New York
|
-$2.57K |
| 5 |
BlackRock
New York
|
-$247 |
ANEB Hedge Fund Activity: Q1 2024 in Review
15 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q1 2024, worth a combined $21M — up 19% from $17.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ANEB positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $65K. The largest seller was Landscape Capital Management, exiting entirely with an estimated $36.3K sold.
- 15 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q1 2024, up from 14 in Q4 2023.
- Funds reported $21M of Anebulo Pharmaceuticals stock for Q1 2024, up 19% quarter-over-quarter.
- 4 funds opened new Anebulo Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of +1 holder.
- The largest Anebulo Pharmaceuticals buyer in Q1 2024 was Susquehanna International Group, an estimated $65K added.
- The largest Anebulo Pharmaceuticals seller in Q1 2024 was Landscape Capital Management, an estimated $36.3K sold.
Based on aggregated 13F filings for Q1 2024.